Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Assets (2016 - 2025)

Sangamo Therapeutics (SGMO) has disclosed Current Assets for 16 consecutive years, with $35.8 million as the latest value for Q4 2025.

  • For Q4 2025, Current Assets fell 30.68% year-over-year to $35.8 million; the TTM value through Dec 2025 reached $35.8 million, down 30.68%, while the annual FY2025 figure was $35.8 million, 30.68% down from the prior year.
  • Current Assets hit $35.8 million in Q4 2025 for Sangamo Therapeutics, down from $44.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $606.9 million in Q1 2021 and bottomed at $35.8 million in Q4 2025.
  • Average Current Assets over 5 years is $217.1 million, with a median of $153.6 million recorded in 2023.
  • Year-over-year, Current Assets soared 63.62% in 2021 and then tumbled 74.89% in 2024.
  • Sangamo Therapeutics' Current Assets stood at $398.8 million in 2021, then fell by 24.69% to $300.3 million in 2022, then crashed by 68.59% to $94.3 million in 2023, then tumbled by 45.2% to $51.7 million in 2024, then crashed by 30.68% to $35.8 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $35.8 million, $44.1 million, and $49.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.